DRMA 10-Q: SEC filing

Dermata Therapeutics

Filed with the SEC on Nov 10, 2026 · accession 0001493152-26-050967

DRMA filed a 10-Q (quarterly report) with the SEC on Nov 10, 2026. Dermata Therapeutics filed its Q3 2026 Form 10-Q, reporting routine quarterly financial results including a net loss and ongoing clinical-stage operations. The stock moved -7.2% by the first close after the filing.

Summary of the filing

Dermata Therapeutics filed its Q3 2026 Form 10-Q, reporting routine quarterly financial results including a net loss and ongoing clinical-stage operations. The filing also discloses recent financing activities, including an August 2026 private placement of common stock and warrants.

For details, click here →How to read a 10-Q →

Key details

FilerDermata Therapeutics, Inc.

How DRMA stock reacted

Close before

$0.77

Nov 9, 2026

First close after

-7.21%

$0.71

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for DRMA, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for DRMA?

Click here

Frequently asked questions

What did DRMA file with the SEC on Nov 10, 2026?

DRMA filed a 10-Q (SEC filing). Dermata Therapeutics filed its Q3 2026 Form 10-Q, reporting routine quarterly financial results including a net loss and ongoing clinical-stage operations. The filing also discloses recent financing activities, including an August 2026 private placement of common stock and warrants.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

How did DRMA stock react to this filing?

DRMA closed at $0.77 before the filing and $0.71 on Nov 10, 2026 (-7.21%).

Other DRMA SEC filings

Get alerts when DRMA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

DRMA overview DRMA analysis DRMA news Latest SEC filings